ABSTRACT
Background Acute kidney injury (AKI) is an important risk factor associated with adverse outcomes in cardiovascular illnesses, more importantly, myocardial infarction (MI). This study describes the Trends, in-hospital outcomes, and independent predictors of Acute Kidney Injury (AKI) in patients admitted for Myocardial infarction with Percutaneous Coronary Intervention (PCI).
Methods This retrospective study used patient records from the 2016-2020 National In-patient Database (NIS). We identified patients who were admitted for the management of an MI who had a PCI procedure and an AKI and evaluated their associated socio-demographic and comorbid factors using International Classification of Diseases-10 (ICD-10) codes. The chi-square test was used to compare baseline characteristics between our populations with and without AKI and outcomes and multivariate logistic regression to identify independent predictors of AKI.
Results There were 1,551,630 patients admitted for an MI and PCI, with 15% having an AKI. We observed that our population with AKI were older on admission and were more likely to be whites than blacks. A higher percentage were males. Our subpopulation was likely to have heart failure, atrial fibrillation, coronary artery disease, obesity, CKD and Charlson comorbidity index ≥ 3. A diagnosis of AKI was associated with higher in-hospital mortality rates [adjusted odds ratio (aOR): 2.84, CI: 2.7–3.02, p<0.001], longer mean length of stay (LOS) and higher hospital costs. We noted an increasing trend in the percentage of patients who had an AKI, from about 13.5% in 2016 to 16.5% in 2020.
Conclusion Acute Kidney Injury is strongly associated with worse hospital outcomes in patients admitted for MI and PCI, with higher mortality rates, a longer mean length of stay, and a higher hospitalization cost. A more concise look at preventive measures is recommended to minimize these outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external fundings
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was not submitted for research ethics approval as the activities described were conducted as part of the Nationwide Inpatient Sample Database (NIS), which is part of the family of databases and software tools developed for the Healthcare Cost and Utilization Project (HCUP) and uses de-identified data collected from hospitalized patients. Consent was not obtained, given the use of a de-identified database. All the experiments in our study were under the guidelines and agreement regulations of the Agency Healthcare Research and Quality (AHRQ)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated and analyzed during the current study are available in the Healthcare Cost and Utilization Project National Data Registry. This Data Use Agreement ('Agreement') governs the disclosure and use of data in the HCUP Nationwide Databases from the Healthcare Cost and Utilization Project (HCUP), which the Agency maintains for Healthcare Research and Quality (AHRQ). Accordingly, HCUP Databases may only be released in 'limited data set' form, as the Privacy Rule defines that term, 45 C.F.R. part 164.514(e). In addition, AHRQ classifies HCUP data as protected health information under the HIPAA Privacy Rule, 45 C.F.R. part 160.103. The datasets generated and analyzed during the current study are not publicly available except for the corresponding author who purchased the data and signed the HCUP Data Use agreement training. Researchers should readily be able to publicly purchase the same databases we did to conduct research.
